Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hatem A Azim

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
JAMA Oncology|December 4, 2015
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer RecurrenceMichail Ignatiadis, Hatem A Azim, Christine Desmedt, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Breast (Edinburgh, Scotland)|February 14, 2026
Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysisLuca Arecco, Pedro M Cacilhas, Camila Bobato Lara Gismondi, et al.
Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyRina Hui, Alex Pearson, Javier Cortes, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Pregnancy After Breast Cancer: A Systematic Review and Meta-AnalysisMatteo Lambertini, Eva Blondeaux, Marco Bruzzone, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
JAMA Oncology|December 4, 2015
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer RecurrenceMichail Ignatiadis, Hatem A Azim, Christine Desmedt, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Breast (Edinburgh, Scotland)|February 14, 2026
Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysisLuca Arecco, Pedro M Cacilhas, Camila Bobato Lara Gismondi, et al.
Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyRina Hui, Alex Pearson, Javier Cortes, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Pregnancy After Breast Cancer: A Systematic Review and Meta-AnalysisMatteo Lambertini, Eva Blondeaux, Marco Bruzzone, et al.
Pageof 14